Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Oct 17

PMID 36245969

Authors

Xin Liu

Meng Fu

Daqing Xia

Zimei Ji

Nana Hu

Zaijun Leng

Wang Xie

Yuan Fang

Junqiang Zhang

Affiliations

Soon will be listed here.

Abstract

Family with sequence similarity 83, member A (FAM83A) plays an essential and fundamental role in the proliferation, progression, and apoptosis of many malignant tumors, including lung cancer. This study aimed to determine the expression pattern of FAM83A in lung adenocarcinoma (LUAD) and its correlation with the prognosis of cancer and the survival of the patients. Bioinformatics analysis, immunohistochemistry, and Western blotting were used to explore and detect the expression of FAM83A in LUAD cells. The mechanism of FAM83A in proliferation and migration was examined. The correlation between FAM83A expression and survival rate was assessed by the Kaplan-Meier and Cox regression. FAM83A expression was elevated in LUAD tissues and was related to shorter overall survival ( < 0.05). A significant increase in FAM83A protein was observed in the LUAD tissue ( < 0.05). Compared with patients with early-stage tumors (stage I-II), those with advanced stage tumors (stage III-IV) had significantly higher FAM83A expression levels ( < 0.05). Downregulation of FAM83A led to a reduction in cell proliferation, a decrease in migration ability, and diminished epithelial-mesenchymal transition (EMT) in the lung cancer cell lines. Overexpression of FAM83A was associated with early lymph node metastasis and poor overall survival among LUAD patients. The findings indicated that FAM83A may play a critical role in promoting the LUAD progression and thus might serve as a novel prognostic marker in LUAD.

Citing Articles

Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.

Liu H, Yao J, Liu Y, Wu L, Tan Z, Hu J Discov Oncol. 2024; 15(1):242.

PMID: 38914812 PMC: 11196556. DOI: 10.1007/s12672-024-01109-7.

Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin.

Wang Y, Zhang T, Du H, Yang M, Xie G, Liu T Oncol Rep. 2023; 50(2).

PMID: 37449493 PMC: 10360146. DOI: 10.3892/or.2023.8598.

Cuproptosis Depicts Immunophenotype and Predicts Immunotherapy Response in Lung Adenocarcinoma.

Zhou W, Cheng Y, Li L, Zhang H, Li X, Chang R J Pers Med. 2023; 13(3).

PMID: 36983664 PMC: 10051631. DOI: 10.3390/jpm13030482.

References

Brody H . Lung cancer. Nature. 2020; 587(7834):S7. DOI: 10.1038/d41586-020-03152-0. View

Hu H, Wang F, Wang M, Liu Y, Wu H, Chen X . FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Int J Med Sci. 2020; 17(6):807-814. PMC: 7085261. DOI: 10.7150/ijms.33992. View

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S . Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017; 31(2):225-239. PMC: 5501076. DOI: 10.1016/j.ccell.2017.01.005. View

Liu P, Chen Y, Tsai K, Yeah H, Yeh C, Tu Y . Involvement of MicroRNA-1-FAM83A Axis Dysfunction in the Growth and Motility of Lung Cancer Cells. Int J Mol Sci. 2020; 21(22). PMC: 7700477. DOI: 10.3390/ijms21228833. View

Oxnard G, Arcila M, Sima C, Riely G, Chmielecki J, Kris M . Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2010; 17(6):1616-22. PMC: 3060283. DOI: 10.1158/1078-0432.CCR-10-2692. View

Fulcher L, Bozatzi P, Tachie-Menson T, Wu K, Cummins T, Bufton J . The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Sci Signal. 2018; 11(531). PMC: 6025793. DOI: 10.1126/scisignal.aao2341. View

Ji H, Song H, Wang Z, Jiao P, Xu J, Li X . FAM83A promotes proliferation and metastasis via Wnt/β-catenin signaling in head neck squamous cell carcinoma. J Transl Med. 2021; 19(1):423. PMC: 8507380. DOI: 10.1186/s12967-021-03089-6. View

Zhou F, Wang X, Liu F, Meng Q, Yu Y . FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. Int J Clin Oncol. 2020; 25(9):1612-1623. DOI: 10.1007/s10147-020-01696-9. View

10.

Shi R, Jiao Z, Yu A, Wang T . Long noncoding antisense RNA FAM83A-AS1 promotes lung cancer cell progression by increasing FAM83A. J Cell Biochem. 2019; 120(6):10505-10512. PMC: 6590457. DOI: 10.1002/jcb.28336. View

11.

Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y . BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia. 2005; 7(12):1073-80. PMC: 1501171. DOI: 10.1593/neo.05406. View

12.

Chen S, Huang J, Liu Z, Liang Q, Zhang N, Jin Y . FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogenesis. 2017; 6(3):e300. PMC: 5533946. DOI: 10.1038/oncsis.2017.3. View

13.

Ke A, Shi G, Zhou J, Huang X, Shi Y, Ding Z . CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology. 2011; 140(5):1629-41.e15. DOI: 10.1053/j.gastro.2011.02.008. View

14.

Bartel C, Parameswaran N, Cipriano R, Jackson M . FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget. 2016; 7(32):52597-52612. PMC: 5239576. DOI: 10.18632/oncotarget.9544. View

15.

Han J, Park K, Kim S, Lee D, Kim H, Kim H . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30(10):1122-8. DOI: 10.1200/JCO.2011.36.8456. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Grant S . FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. J Clin Invest. 2012; 122(9):3048-51. PMC: 3428099. DOI: 10.1172/JCI64412. View

18.

Aiello N, Kang Y . Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019; 216(5):1016-1026. PMC: 6504222. DOI: 10.1084/jem.20181827. View

19.

Liu L, Liao G, He P, Zhu H, Liu P, Qu Y . Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun. 2008; 372(4):756-60. DOI: 10.1016/j.bbrc.2008.05.101. View

20.

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View